Analysts expect that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will announce ($0.53) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Spring Bank Pharmaceuticals’ earnings, with estimates ranging from ($0.86) to ($0.37). Spring Bank Pharmaceuticals posted earnings per share of ($0.51) in the same quarter last year, which would suggest a negative year-over-year growth rate of 3.9%. The business is expected to report its next earnings results on Wednesday, February 21st.

According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full year earnings of ($2.65) per share for the current fiscal year, with EPS estimates ranging from ($3.35) to ($1.75). For the next year, analysts forecast that the company will post earnings of ($2.08) per share, with EPS estimates ranging from ($3.62) to ($1.67). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Spring Bank Pharmaceuticals.

Several analysts have issued reports on SBPH shares. Cantor Fitzgerald set a $29.00 target price on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 16th. B. Riley started coverage on Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They issued a “buy” rating and a $30.00 target price on the stock. ValuEngine lowered Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Chardan Capital reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. Finally, Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $27.25.

Large investors have recently added to or reduced their stakes in the stock. DAFNA Capital Management LLC bought a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter valued at $217,000. C WorldWide Group Holding A S bought a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter valued at $340,000. EAM Investors LLC bought a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter valued at $578,000. Vanguard Group Inc. bought a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter valued at $794,000. Finally, Morse Asset Management Inc raised its stake in shares of Spring Bank Pharmaceuticals by 156.9% during the 2nd quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock valued at $862,000 after purchasing an additional 38,900 shares during the period. Institutional investors own 29.70% of the company’s stock.

Shares of Spring Bank Pharmaceuticals (NASDAQ:SBPH) traded down $0.23 on Tuesday, hitting $13.50. The company’s stock had a trading volume of 9,871 shares, compared to its average volume of 34,085. Spring Bank Pharmaceuticals has a 52-week low of $6.31 and a 52-week high of $18.93.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.53 Per Share” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/05/brokerages-expect-spring-bank-pharmaceuticals-inc-sbph-will-post-earnings-of-0-53-per-share.html.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.